Topic - Novartis Ag

Subscribe to this topic via RSS or ATOM
Related Stories
  • Pfizer ups offer for AstraZeneca again, to $119B

    U.S. drugmaker Pfizer said Sunday that it has raised its offer for British rival AstraZeneca for a third time, hiking its stock-and-cash offer by 15 percent to $118.8 billion, or 70.73 billion pounds.

  • FILE - The Oct. 19, 2012 file photo shows a Novartis employee in a laboratory of Novartis in Prangins near Nyon, Switzerland. Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday, April 22, 2014 with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.  (AP Photo/Keystone, Yannick Bailly)

    Novartis reshapes business with GSK, Lilly deals

    Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that heralds more restructuring in the fast-changing industry.

  • ** FILE ** In this Thursday, Feb. 9, 2012, file photo, a pharmacist works in a lab where medicines are being produced at a Cipla manufacturing unit on the outskirts of Mumbai, India. A lawyer for healthcare activists says India's Supreme Court has rejected drug maker Novartis AG' right to patent a new version of a lifesaving cancer drug. (AP Photo/Rafiq Maqbool, File)

    Drug maker Novartis loses India patent battle

    India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines.

  • ** FILE ** In this March 13, 2012, file photo, Indian scientists work inside a laboratory of the Research and Development Centre of Natco Pharma Ltd. in Hyderabad, India. (AP Photo/Mahesh Kumar A., File)

    Indian court to rule on generic drug industry

    From Africa's crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will determine whether India's drug companies can continue to provide cheap versions of many life-saving medicines.

  • Indian court to rule on generic drug industry

    From Africa's crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will determine whether India's drug companies can continue to provide cheap versions of many life-saving medicines.

  • EU drug regulator OKs Novartis' meningitis B shot

    Europe's top drug regulator has recommended approval for the first vaccine against meningitis B, made by Novartis AG.

  • EU approves Afinitor for certain breast cancers

    Swiss drug maker Novartis AG says it has received European approval to market Afinitor for treatment of women with the most common form of advanced breast cancer.

  • New drugs shore up Novartis in Q2

    Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines and the strengthening dollar.

  • Novartis tries to make UK hospitals use $1000 drug

    Drug maker Novartis is taking legal action in Britain to make state-run hospitals use an eye drug that costs about 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

  • Novartis drug investigated after 11 deaths

    A European agency is investigating a multiple sclerosis drug made by industry giant Novartis to determine whether the medicine played any role in the deaths at least 11 patients.

  • Big promise is seen in 2 new breast cancer drugs

    Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse.

  • Novartis fights patent rejection in Indian court

    In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis AG for its lifesaving cancer treatment Gleevec.

  • Novartis receives OK to market eye drug in Europe

    Swiss pharmaceutical company Novartis AG says it has received approval from European regulators to market a new drug to treat vision problems resulting from diabetes.

  • Correction: Breast Cancer-Bone Drug story

    In a Dec. 9 story about Novartis AG's Reclast drug, The Associated Press erroneously described it as a twice-a-year treatment for osteoporosis. Reclast is given as an infusion once every two years for preventing osteoporosis in older women, and once a year to treat the disease.

  • Bone drug Zometa flops in breast cancer study

    One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from returning or extend life for most women fighting the disease.

More Stories →

Happening Now